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ABSTRACT 
 
Background Calcineurin inhibitors post renal transplantation are recognised to 
cause tubulopathies in the form of hyponatremia, hyperkalemia and acidosis. Sodium 
supplementation may be required, increasing medication burden and potentially 
resulting in poor compliance. Fludrocortisone has been beneficial in addressing 
tubulopathies in adult studies, with limited paediatric data available. Methods A 
retrospective review of data from an electronic renal database from December 2014 
to January 2016. Results 47 post-transplant patients were reviewed with 23 (49%) 
patients on sodium chloride or bicarbonate. 9 patients, aged 8.3 years (range 4.9-
16.4) commenced fludrocortisone 22 months (range 1-80) after transplant and were 
followed up for 9 months (range 2-20). All patients stopped sodium bicarbonate; all 
had a reduction or no increase in total daily doses of sodium chloride. Potassium 
levels were significantly lower on fludrocortisone, 5.2 vs 4.5 mmol/l, p=0.04. No 
difference was noted in renal function (eGFR 77.8 vs 81.7 ml/min/1.73m2, p=0.45) 
and no significant increase in systolic blood pressure (z-scores 0.99 vs 0.85, p=0.92). 
No side effects secondary to treatment with fludrocortisone were reported. 
Conclusions A significant proportion of renal transplant patients were on sodium 
supplementation. Fludrocortisone reduced sodium supplementation without 
significant effects on renal function or blood pressure. Fludrocortisone appears to be 
safe and effective for tubulopathies in children post transplantation. 
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INTRODUCTION 
 
Tubulopathy, in the form of hyperkalaemia, metabolic acidosis and salt-wasting 
syndromes, has been recognised in the literature, post transplantation1,2. However, 
the incidence of this type 4 renal tubular acidosis remains unknown. Whilst tubular 
dysfunction can occur secondary to renal impairment and interstitial damage from 
acute episodes and nephrotoxic drugs3; immunosuppressive regimens, namely 
calcineurin inhibitors (CNI) (Ciclosporin, Tacrolimus) have also been directly 
implicated4,5,6. These drugs are thought to lead to a down regulation of the 
mineralocorticoid receptors and a resultant pseudohypoaldosteronism picture with 
normal aldosterone levels. There is perhaps a suggestion that tubulopathy is more 
associated with tacrolimus than ciclosporin5 with transplant immunosuppressive 
regimens now more likely to use the former. 
 Fludrocortisone, a corticosteroid with high glucocorticoid and potent 
mineralocorticoid activity, has been shown to be beneficial when used in adults with 
end-stage renal disease (ESRD) who are anuric, on haemodialysis and 
hyperkalaemic7. In managing CNI associated hyperkalaemia, adult literature reports 
a small number of cases with a beneficial response to fludrocortisone, and 
emphasises the benefits of fludrocortisone as a safe and effective treatment in 
reversing post transplant tubulopathies with normalisation of electrolytes8,9,10. 
Tubulopathy when occurring post transplantation requires the initiation of 
electrolyte supplementation, particularly sodium bicarbonate and sodium chloride 
replacement, to aid amongst other factors, growth. However, this adds to the 
medication burden, potentially therefore affecting compliance11. 
Paediatric data remains limited with only one centre reporting the efficacy of 
fludrocortisone in a paediatric population for management of tubulopathy post renal 
transplantation12. We report our national experience of the efficacy of fludrocortisone 
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in the management of post renal transplant tubulopathy and its potential benefits in 
paediatric renal transplantation. 
 
MATERIALS AND METHODS 
 
A retrospective case review of data collected from a multi-centre, electronic renal 
patient database (Strathclyde Electronic Renal Patient Record, SERPR) was 
undertaken over a 14 month time period from December 2014 to January 2016. Data 
was collected for all paediatric renal transplant recipients reviewed in the tertiary 
paediatric renal service during the study period. 
Patient demographics, medication, dietary regimens and renal function data 
was collected for all patients who were commenced on sodium supplements and 
subsequently fludrocortisone post renal transplantation. Patients were commenced 
on an initial total daily dose of between 25-50 micrograms of fludrocortisone with two 
patients commenced on a starting dose of 100 micrograms (range 0.8-4.0 
µg/kg/day). Dose increment adjustments of 25-50 micrograms were made depending 
on tolerance, biochemistry results, concurrent electrolyte supplementation and blood 
pressure measurements. Maximum dose ranges from 75 to 150 micrograms, were 
used for all patients other than one patient who had a maximum dose of 200 
micrograms at follow-up (range 2.9-8.1 µg/kg/day). All patients were given a once 
daily oral preparation of fludrocortisone. Blood pressure measurements were 
referenced as per standard accepted 4th Task Force Report data13.  
Non-parametric data was analysed using paired t-tests to compare pre-
treatment and treatment values (on fludrocortisone). The results are presented as 
median and range intervals.   
Ethics approval was not required as this was a retrospective case-series 
corresponding to service audit. 
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RESULTS 
 
Clinical and demographic data 
 
Forty-seven (35 males and 12 females) paediatric renal transplant recipients were 
identified from the SERPR database and reviewed in the tertiary paediatric renal 
service during the study period. 23 (17 males) patients (48.9%) were commenced on 
sodium supplementation (sodium chloride, sodium bicarbonate).  Of the cohort of 
patients commenced on sodium supplementation, 6 were also commenced on 
fludrocortisone. A further 3 patients were commenced directly onto fludrocortisone to 
directly manage tubular dysfunction post transplantation. A total of 9 patients 
received fludrocortisone (Table 1). Two of the 3 patients commenced directly onto 
fludrocortisone had previously been on sodium supplementation but not during the 
study period. 
The median age of patients commenced on fludrocortisone was 8.3 years 
(range 4.9-16.4). Fludrocortisone was given at a median of 22 months (range 1-80) 
after renal transplantation. Patients were followed up for a median of 9 months 
(range 2-20) after commencing fludrocortisone, this was equal to the time from 
commencing fludrocortisone to attaining the maximum dose of fludrocortisone.  
All 9 patients were taking tacrolimus post transplantation, with a median 
tacrolimus trough level of 6.7 ng/ml (range 2.7-10.4). Five patients (Table 1, Patients 
3-6, 7) were additionally taking mycophenolate mofetil (MMF) post transplant. No 
patients were on a maintenance steroid medication regimen. 
 
Effect on sodium supplementation 
 
At follow-up, all patients commenced on fludrocortisone therapy were able to 
discontinue sodium bicarbonate supplementation and either had a reduction or no 
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increase in the total daily dose of sodium chloride (Table 1). In the 3 patients who 
commenced fludrocortisone prior to electrolyte supplementation, sodium and 
bicarbonate values stabilised. Pre-treatment sodium levels (mmol/l) were 132, 134 
and 132 and on the maximum dose of fludrocortisone, post-treatment were 138, 141 
and 137. Pre-treatment bicarbonate levels (mmol/l) were 21, 18, 16 and post-
treatment levels were 23, 22 and 21. 
 
Effect on renal function, serum potassium and blood pressure 
 
There was no significant change in renal function. The median eGFR (calculated 
using the Schwartz formula14) pre-treatment was 77.8 compared to 81.7 
ml/min/1.73m2 on the maximum dose of fludrocortisone, p=0.45 (Fig. 1a).  
Serum potassium levels (Fig. 1b) were significantly lower following treatment 
with fludrocortisone, 5.2 compared to 4.5 mmol/l, p=0.04. Two patients had received 
specific dietetic advice on maintaining a low potassium diet prior to commencing 
fludrocortisone. One patient in this cohort had a strict potassium restricted diet; this 
patient was not on electrolyte supplementation prior to treatment with fludrocortisone. 
There was no significant effect on blood pressure following treatment with 
fludrocortisone, systolic BP 107 compared to 106 mmHg, p=0.81; diastolic BP 68 
compared to 66 mmHg, p= 0.37.  In addition, there was no significant difference in 
median systolic blood pressure z-scores (based on age, height and gender) before 
and whilst on fludrocortisone, 0.99 vs 0.85, p= 0.92 (Fig. 1c). Three patients were 
taking amlodipine as an antihypertensive agent prior to commencing fludrocortisone. 
Of these, one patient had commenced amlodipine one month prior to fludrocortisone 
and two patients had started amlodipine one year prior to treatment with 
IOXGURFRUWLVRQH$OO SDWLHQWV¶ DQWLK\SHUWHQVLYHGRVHV UHPDLQHGXQFKDQJHGDW IROORZ-
up. 
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There were no side effects of treatment with fludrocortisone reported in this 
cohort, requiring cessation of therapy. 
 
DISCUSSION 
 
There remains an ongoing debate regarding the development of tubulopathies post 
renal transplantation with perhaps under recognition in clinical practice. Acute 
nephrotoxic injuries certainly contribute in many cases, however, CNI based 
immunosuppressive regimens are certainly recognised to cause tubular 
dysfunction2,4,5,6. Renal transplant patients treated with CNIs such as ciclosporin A 
and tacrolimus (FK 506) may develop signs of partial resistance to aldosterone 
action with subsequent hyperkalaemia and metabolic acidosis2, thus, partially 
explaining the mechanism of action of fludrocortisone in this setting. These 
electrolyte imbalances are believed to be the result of direct inhibitory effects on the 
ion±exchange systems of the distal tubule of the nephron such as the Na-K-ATPase 
and Na-K-2Cl co-transporters. Despite normal aldosterone levels in these patients, 
increased inactive renin levels in transplant recipients suggest a disturbance with the 
Renin-Angiotensin-Aldosterone System. Heering et al4 described aldosterone 
resistance presenting as hyperkalaemia and metabolic acidosis post transplantation 
with ciclosporin and a potential association with downregulation of mineralocorticoid 
receptor expression on peripheral leukocytes.  
  Fludrocortisone, with its dual glucocorticoid and mineralocorticoid role, acts 
via the Na-K pump in the renal tubule. The intracellular shift of potassium may play a 
role in the potassium lowering effect of fludrocortisone. The use of fludrocortisone as 
a treatment for tubulopathies post paediatric renal transplantation remains a novel 
approach. The retrospective case series of 15 paediatric patients by Bacchetta et al12 
reported a significant reduction in sodium supplementation following treatment with 
fludrocortisone. However, a significant increase in blood pressure was also noted in 
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this cohort and almost half (47%) were receiving anti-hypertensives prior to 
commencing fludrocortisone. Thus, it may be speculated that their cohort was at 
µKLJK ULVN¶ RI K\SHUWHQVLRQ SULRU WR WUHDWPHQW ZLWK IOXGURFRUWLVRQH ,Q DGGLWLRQ WKH
prevailing immunosuppressive regimen was not clear in their cohort, including the 
presence of a steroid based regimen, which may have contributed to the increase in 
blood pressure observed. The primary renal diagnoses in their cohort were not 
dissimilar from that in our study. Furthermore, Bacchetta et al reported that 6 patients 
(40%) required cessation of treatment due to side effects of fludrocortisone (including 
hypertension, gastric pain or hypokalaemia), parental decision or non-compliance. 
The initial fludrocortisone dosing regimens in this study and that by Bacchetta et al 
are similar. However, Bacchetta et al report using a higher dosing increment of up to 
ȝJNJGD\LQWKHLU cohort, which may account for the increased side effect profile 
in their study. 
Due to the large range of tacrolimus levels and small numbers in our cohort, 
we were unable to determine whether tubular CNI related adverse effects were dose 
related. However, our study noted a reduction in electrolyte supplementation, a 
reduction in serum potassium levels with no change in renal function and no change 
in blood pressure at follow-up. The hypokalaemic properties of fludrocortisone are an 
added benefit as patients on a potassium restricted diet were able to liberalise their 
dietary potassium intake.  
Maintenance steroids are variably used in post renal transplant 
immunosuppressive regimens. This regimen even with the inclusion of tacrolimus 
may partially mask tubular dysfunction in post renal transplant populations. 
Our study has demonstrated that fludrocortisone is well tolerated, with no side 
effects occurring secondary to treatment in our cohort. The insignificant differences in 
eGFR and blood pressure are unlikely to be due to the short interval as some 
patients were followed up for up to 20 months. However, a longer period of follow-up 
would be ideal and on going follow-up is still required to monitor for long-term side 
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effects. It is important to be mindful of the side effect profile of fludrocortisone which 
may include hypertension, oedema secondary to salt and water retention, 
hypokalaemia and gastric upset and patients should be counseled appropriately prior 
to commencing treatment.  
Limitations of our study include a small patient cohort. Furthermore, due to 
limited experience in the use of fludrocortisone in the management of tubulopathy 
post paediatric renal transplantation, there is currently no guidance with regards to 
an optimum dosing regimen in this setting. We used a starting dose of 25 to 50 
micrograms of fludrocortisone, a dose similar to that used in children with salt 
wasting endocrinopathies15. This study needs to be replicated in larger cohorts with 
varying dosing regimens in order to minimise the potential side effect profile whilst at 
the same time maximising the efficacy of treatment with fludrocortisone. The analysis 
of additional data parameters including height and weight which are routinely 
collected in the clinical setting may also be useful in future studies to determine the 
potential effects of fludrocortisone on growth and development in children. 
Measurements of plasma renin and aldosterone may also be useful in future studies. 
In summary, tubulopathy in children post renal transplantation can be 
managed by fludrocortisone, which has been shown to reduce the requirement for 
electrolyte supplementation. Additionally, in our study, as fludrocortisone did not 
show a significant effect on renal function or blood pressure, it suggests it is a safe 
and effective treatment option for this indication. This study adds to the limited 
evidence in the literature regarding the benefits of fludrocortisone in the management 
of tubulopathy post renal transplantation. 
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Table 1. Patients commenced on fludrocortisone 
 
Patient 
 
Renal diagnosis Fludrocortisone  
(mcg) 
NaHCO3  
(g) 
NaCl  
(g) 
Initial 
dose 
Max 
dose 
Pre-
Fludro 
With 
Fludro 
Pre-
Fludro 
With 
Fludro 
 
1 
2 
3 
4 
5 
6 
 
Prune belly syndrome 
Posterior urethral valves 
Prune belly syndrome 
Congenital nephrotic syndrome 
Congenital renal hypoplasia 
Congenital nephrotic syndrome 
 
25 
25 
25 
50 
50 
50 
 
100 
150 
150 
75 
150 
100 
 
1.9 
2.0 
6.7 
3.0 
5.0 
1.5 
 
0 
0 
0 
0 
0 
0 
 
2.7 
1.8 
4.0 
1.8 
4.5 
1.2 
 
1.8 
0.9 
0 
1.8 
4.0 
0.6 
7 
8 
9 
Congenital renal hypoplasia 
Congenital renal hypoplasia 
Chronic kidney disease stage 4 
50 
100 
100 
100 
200 
100 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
NaHCO3, sodium bicarbonate; NaCl, sodium chloride; mcg, micrograms; g, grams. 
 
 Patients 1-6 were taking sodium supplements prior to commencing fludrocortisone. 
 Patients 7-9 were commenced directly onto fludrocortisone. 
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Fig 1a. eGFR (ml/min/1.73m2): Before fludrocortisone and at maximum dose of 
fludrocortisone. 
 
Boxplot note: Horizontal line represents median, rectangle represents first and third 
quartiles, whiskers represent 2.5th to 97.5th percentiles. 
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Fig 1b. Serum potassium (mmol/l): Before fludrocortisone and at maximum 
dose of fludrocortisone. 
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Fig 1c. Systolic blood pressure z-scores: Before fludrocortisone and at 
maximum dose of fludrocortisone. 
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